{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:00:25Z","timestamp":1789758025181,"version":"4.0.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guizhou Health and Health Commission Science and Technology Fund Project","award":["gzwkj2024-275"],"award-info":[{"award-number":["gzwkj2024-275"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02492-5","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T14:00:23Z","timestamp":1747058423000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Research on the functions and potential mechanisms of STAT3 in chronic myelogenous leukemia"],"prefix":"10.1007","volume":"16","author":[{"given":"Xiaoyun","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingquan","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"issue":"1","key":"2492_CR1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3390\/cells10010117","volume":"10","author":"VR Minciacchi","year":"2021","unstructured":"Minciacchi VR, Kumar R, Krause DS. Chronic myeloid leukemia: a model disease of the past, present and future. Cells. 2021;10(1):117.","journal-title":"Cells"},{"issue":"3","key":"2492_CR2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.6026\/97320630010108","volume":"10","author":"A Hai","year":"2014","unstructured":"Hai A, Kizilbash NA, Zaidi SH, et al. Differences in structural elements of Bcr-Abl oncoprotein isoforms in chronic myelogenous leukemia. Bioinformation. 2014;10(3):108\u201314.","journal-title":"Bioinformation"},{"issue":"2","key":"2492_CR3","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.survophthal.2021.07.001","volume":"67","author":"MA Yassin","year":"2022","unstructured":"Yassin MA, Ata F, Mohamed SF, et al. Ophthalmologic manifestations as the initial presentation of chronic myeloid leukemia: a review. Surv Ophthalmol. 2022;67(2):530\u201343.","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"2492_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41375-022-01736-5","volume":"37","author":"J Senapati","year":"2023","unstructured":"Senapati J, Jabbour E, Kantarjian H, et al. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. Leukemia. 2023;37(1):5\u201317.","journal-title":"Leukemia"},{"issue":"1","key":"2492_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","volume":"22","author":"NP Shah","year":"2024","unstructured":"Shah NP, Bhatia R, Altman JK, et al. Chronic myeloid leukemia, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22(1):43\u201369.","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"2492_CR6","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747\u201357.","journal-title":"Lancet Oncol"},{"issue":"5","key":"2492_CR7","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.apsb.2015.07.001","volume":"5","author":"L Huang","year":"2015","unstructured":"Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 2015;5(5):390\u2013401.","journal-title":"Acta Pharm Sin B"},{"issue":"2","key":"2492_CR8","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3390\/ijms22020659","volume":"22","author":"Y Yung","year":"2021","unstructured":"Yung Y, Lee E, Chu HT, et al. Targeting abnormal hematopoietic stem cells in chronic myeloid leukemia and philadelphia chromosome-negative classical myeloproliferative neoplasms. Int J Mol Sci. 2021;22(2):659.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2492_CR9","first-page":"350","volume":"28","author":"ZR Cao","year":"2020","unstructured":"Cao ZR, Chen XP, Hu J. Research advance on classic Wnt pathway in chronic myelogenous leukemia-review. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020;28(1):350\u20133.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"3","key":"2492_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1620\/tjem.237.163","volume":"237","author":"L Bi","year":"2015","unstructured":"Bi L, Yu Z, Wu J, et al. Honokiol inhibits constitutive and inducible STAT3 signaling via PU.1-induced SHP1 expression in acute myeloid leukemia cells. Tohoku J Exp Med. 2015;237(3):163\u201372.","journal-title":"Tohoku J Exp Med"},{"issue":"3","key":"2492_CR11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s13238-013-2084-3","volume":"4","author":"Y Fan","year":"2013","unstructured":"Fan Y, Mao R, Yang J. NF-\u03baB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell. 2013;4(3):176\u201385.","journal-title":"Protein Cell"},{"issue":"12","key":"2492_CR12","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1038\/s41375-021-01315-0","volume":"35","author":"SB Patel","year":"2021","unstructured":"Patel SB, Nemkov T, Stefanoni D, et al. Metabolic alterations mediated by STAT3 promotes drug persistence in CML. Leukemia. 2021;35(12):3371\u201382.","journal-title":"Leukemia"},{"issue":"1","key":"2492_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12974-022-02549-0","volume":"19","author":"J Kim","year":"2022","unstructured":"Kim J, Lee HJ, Park JH, et al. Nilotinib modulates LPS-induced cognitive impairment and neuroinflammatory responses by regulating P38\/STAT3 signaling. J Neuroinflam. 2022;19(1):187.","journal-title":"J Neuroinflam"},{"issue":"8","key":"2492_CR14","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1177\/15353702231157934","volume":"248","author":"L Xie","year":"2023","unstructured":"Xie L, Li Y, Tang W, Zhang Q, Luo C, Long X. Stattic alleviates pulmonary fibrosis in a mouse model of rheumatoid arthritis-relevant interstitial lung disease. Exp Biol Med. 2023;248(8):712\u201321.","journal-title":"Exp Biol Med"},{"issue":"1","key":"2492_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40199-020-00326-z","volume":"28","author":"S Jafari","year":"2020","unstructured":"Jafari S, Lavasanifar A, Hejazi MS, Maleki-Dizaji N, Mesgari M, Molavi O. STAT3 inhibitory stattic enhances immunogenic cell death induced by chemotherapy in cancer cells. Daru. 2020;28(1):159\u201369. https:\/\/doi.org\/10.1007\/s40199-020-00326-z.","journal-title":"Daru"},{"issue":"1","key":"2492_CR16","doi-asserted-by":"publisher","first-page":"113634","DOI":"10.1016\/j.yexcr.2023.113634","volume":"429","author":"C Yuan","year":"2023","unstructured":"Yuan C, Yuan M, Li W, et al. The STAT3 inhibitor stattic overcome bortezomib-resistance in multiple myeloma via decreasing PSMB6. Exp Cell Res. 2023;429(1):113634.","journal-title":"Exp Cell Res"},{"issue":"4","key":"2492_CR17","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41388-018-0449-z","volume":"38","author":"P Guha","year":"2019","unstructured":"Guha P, Gardell J, Darpolor J, et al. STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells. Oncogene. 2019;38(4):533\u201348.","journal-title":"Oncogene"},{"issue":"4","key":"2492_CR18","first-page":"e24935","volume":"2","author":"Y Tang","year":"2013","unstructured":"Tang Y, Tian XC. JAK-STAT3 and somatic cell reprogramming. JAKSTAT. 2013;2(4):e24935.","journal-title":"JAKSTAT"},{"issue":"1","key":"2492_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12943-023-01837-4","volume":"22","author":"JE Shin","year":"2023","unstructured":"Shin JE, Kim SH, Kong M, et al. Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia. Mol Cancer. 2023;22(1):177.","journal-title":"Mol Cancer"},{"issue":"6","key":"2492_CR20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11899-018-0474-6","volume":"13","author":"T Zhou","year":"2018","unstructured":"Zhou T, Medeiros LJ, Hu S. Chronic myeloid leukemia: beyond BCR-ABL1. Curr Hematol Malig Rep. 2018;13(6):435\u201345.","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"2492_CR21","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132(4):393\u2013404.","journal-title":"Blood"},{"issue":"1","key":"2492_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41408-024-00977-0","volume":"14","author":"G Semenzato","year":"2024","unstructured":"Semenzato G, Calabretto G, Teramo A, et al. The constitutive activation of STAT3 gene and its mutations are at the crossroad between LGL leukemia and autoimmune disorders. Blood Cancer J. 2024;14(1):13.","journal-title":"Blood Cancer J"},{"issue":"16","key":"2492_CR23","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.2174\/0929867329666220819093117","volume":"30","author":"J Song","year":"2023","unstructured":"Song J, Wang J, Tian S, et al. Discovery of STAT3 inhibitors: recent advances and future perspectives. Curr Med Chem. 2023;30(16):1824\u201347.","journal-title":"Curr Med Chem"},{"issue":"2","key":"2492_CR24","first-page":"799","volume":"77","author":"HFS Al-Zubaidy","year":"2022","unstructured":"Al-Zubaidy HFS, Majeed SR, Al-Koofee DAF. Evaluation of Bax and BCL 2 genes polymorphisms in Iraqi women with breast cancer. Arch Razi Inst. 2022;77(2):799\u2013808.","journal-title":"Arch Razi Inst"},{"issue":"1","key":"2492_CR25","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.4238\/2015.March.20.6","volume":"14","author":"K Yao","year":"2015","unstructured":"Yao K, Xing HC, Wu B, et al. Effect of TIEG1 on apoptosis and expression of Bcl-2\/Bax and Pten in leukemic cell lines. Genet Mol Res. 2015;14(1):1968\u201374.","journal-title":"Genet Mol Res"},{"issue":"7","key":"2492_CR26","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.toxicon.2010.01.024","volume":"55","author":"YJ Chen","year":"2010","unstructured":"Chen YJ, Liu WH, Kao PH, et al. Involvement of p38 MAPK- and JNK-modulated expression of Bcl-2 and Bax in Naja nigricollis CMS-9-induced apoptosis of human leukemia K562 cells. Toxicon. 2010;55(7):1306\u201316.","journal-title":"Toxicon"},{"issue":"1","key":"2492_CR27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2131\/jts.40.115","volume":"40","author":"M Ghasemian","year":"2015","unstructured":"Ghasemian M, Mahdavi M, Zare P, Ali HosseinpourFeizi M. Spiroquinazolinone-induced cytotoxicity and apoptosis in K562 human leukemia cells: alteration in expression levels of Bcl-2 and Bax. J Toxicol Sci. 2015;40(1):115\u201326.","journal-title":"J Toxicol Sci"},{"key":"2492_CR28","doi-asserted-by":"publisher","first-page":"304","DOI":"10.5414\/ALX02520E","volume":"8","author":"T Niehues","year":"2024","unstructured":"Niehues T, von Hardenberg S, Velleuer E. Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing. Allergol Select. 2024;8:304\u201323.","journal-title":"Allergol Select"},{"issue":"1","key":"2492_CR29","doi-asserted-by":"publisher","first-page":"e135937","DOI":"10.1172\/JCI135937","volume":"131","author":"RS Bhansali","year":"2021","unstructured":"Bhansali RS, Rammohan M, Lee P, et al. DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3. J Clin Invest. 2021;131(1):e135937.","journal-title":"J Clin Invest"},{"issue":"37","key":"2492_CR30","doi-asserted-by":"publisher","first-page":"61876","DOI":"10.18632\/oncotarget.18711","volume":"8","author":"A Teramo","year":"2017","unstructured":"Teramo A, Baril\u00e0 G, Calabretto G, et al. STAT3 mutation impacts biological and clinical features of T-LGL leukemia. Oncotarget. 2017;8(37):61876\u201389.","journal-title":"Oncotarget"},{"issue":"4","key":"2492_CR31","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234\u201348.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02492-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02492-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02492-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T14:00:24Z","timestamp":1747058424000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02492-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2492"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02492-5","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"21 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"739"}}